Currently, the two major approaches to the treatment of metastatic melanoma are immunotherapy and molecularly targeted therapies, and there are studies underway to evaluate combination regimens. This study, together with {1-3}, showed that the checkpoint inhibitors ipilimumab (anti CTLA-4 antibody), nivolumab, and pembrolizumab (anti PD-1 antibodies) result in objective responses in 10-40% of patients and an overall survival benefit. This Recommendation is of an article referenced in an F1000 Faculty Review also written by Iwei Yeh.